Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

Merrill Benson, Barbara Kluve-Beckerman, Steven R. Zeldenrust, Angela M. Siesky, Diane M. Bodenmiller, Aaron D. Showalter, Kyle W. Sloop

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Transthyretin (TTR) amyloidosis, the most common form of hereditary systemic amyloidosis, is characterized clinically by adult-onset axonal neuropathy and restrictive cardiomyopathy. More than 85 mutations in transthyretin have been found to cause this hereditary disease. Since essentially all circulating TTR is of hepatic origin, orthotopic liver transplantation has been used as the only specific form of therapy. Unfortunately, in many patients amyloid deposition continues after orthotopic liver transplantation, indicating that mutant TTR is no longer required for progression of the disease after tissue deposits have been initiated. As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. A transgenic mouse model carrying the human TTR Ile84Ser mutation was created and shown to express high levels of human mutant transthyretin. TTR ASOs suppressed hepatic TTR mRNA levels and serum TTR levels by as much as 80%. Suppression of hepatic synthesis of transthyretin may offer a medical treatment for transthyretin systemic amyloidosis.

Original languageEnglish
Pages (from-to)609-618
Number of pages10
JournalMuscle and Nerve
Volume33
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Prealbumin
Antisense Oligonucleotides
Liver
Liver Transplantation
Familial Amyloidosis
Restrictive Cardiomyopathy
Mutation
Inborn Genetic Diseases
Amyloid
Transgenic Mice
Disease Progression
Therapeutics
Messenger RNA

Keywords

  • Amyloidosis
  • Antisense oligonucleotide (ASO)
  • Cardiomyopathy
  • DNA
  • Familial amyloidotic polyneuropathy
  • Hereditary systemic amyloidosis
  • Transgenic mouse model

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Benson, M., Kluve-Beckerman, B., Zeldenrust, S. R., Siesky, A. M., Bodenmiller, D. M., Showalter, A. D., & Sloop, K. W. (2006). Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle and Nerve, 33(5), 609-618. https://doi.org/10.1002/mus.20503

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. / Benson, Merrill; Kluve-Beckerman, Barbara; Zeldenrust, Steven R.; Siesky, Angela M.; Bodenmiller, Diane M.; Showalter, Aaron D.; Sloop, Kyle W.

In: Muscle and Nerve, Vol. 33, No. 5, 05.2006, p. 609-618.

Research output: Contribution to journalArticle

Benson, M, Kluve-Beckerman, B, Zeldenrust, SR, Siesky, AM, Bodenmiller, DM, Showalter, AD & Sloop, KW 2006, 'Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides', Muscle and Nerve, vol. 33, no. 5, pp. 609-618. https://doi.org/10.1002/mus.20503
Benson M, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle and Nerve. 2006 May;33(5):609-618. https://doi.org/10.1002/mus.20503
Benson, Merrill ; Kluve-Beckerman, Barbara ; Zeldenrust, Steven R. ; Siesky, Angela M. ; Bodenmiller, Diane M. ; Showalter, Aaron D. ; Sloop, Kyle W. / Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. In: Muscle and Nerve. 2006 ; Vol. 33, No. 5. pp. 609-618.
@article{68a22b71f0da422d89dc739ef8c6e305,
title = "Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides",
abstract = "Transthyretin (TTR) amyloidosis, the most common form of hereditary systemic amyloidosis, is characterized clinically by adult-onset axonal neuropathy and restrictive cardiomyopathy. More than 85 mutations in transthyretin have been found to cause this hereditary disease. Since essentially all circulating TTR is of hepatic origin, orthotopic liver transplantation has been used as the only specific form of therapy. Unfortunately, in many patients amyloid deposition continues after orthotopic liver transplantation, indicating that mutant TTR is no longer required for progression of the disease after tissue deposits have been initiated. As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. A transgenic mouse model carrying the human TTR Ile84Ser mutation was created and shown to express high levels of human mutant transthyretin. TTR ASOs suppressed hepatic TTR mRNA levels and serum TTR levels by as much as 80{\%}. Suppression of hepatic synthesis of transthyretin may offer a medical treatment for transthyretin systemic amyloidosis.",
keywords = "Amyloidosis, Antisense oligonucleotide (ASO), Cardiomyopathy, DNA, Familial amyloidotic polyneuropathy, Hereditary systemic amyloidosis, Transgenic mouse model",
author = "Merrill Benson and Barbara Kluve-Beckerman and Zeldenrust, {Steven R.} and Siesky, {Angela M.} and Bodenmiller, {Diane M.} and Showalter, {Aaron D.} and Sloop, {Kyle W.}",
year = "2006",
month = "5",
doi = "10.1002/mus.20503",
language = "English",
volume = "33",
pages = "609--618",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

AU - Benson, Merrill

AU - Kluve-Beckerman, Barbara

AU - Zeldenrust, Steven R.

AU - Siesky, Angela M.

AU - Bodenmiller, Diane M.

AU - Showalter, Aaron D.

AU - Sloop, Kyle W.

PY - 2006/5

Y1 - 2006/5

N2 - Transthyretin (TTR) amyloidosis, the most common form of hereditary systemic amyloidosis, is characterized clinically by adult-onset axonal neuropathy and restrictive cardiomyopathy. More than 85 mutations in transthyretin have been found to cause this hereditary disease. Since essentially all circulating TTR is of hepatic origin, orthotopic liver transplantation has been used as the only specific form of therapy. Unfortunately, in many patients amyloid deposition continues after orthotopic liver transplantation, indicating that mutant TTR is no longer required for progression of the disease after tissue deposits have been initiated. As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. A transgenic mouse model carrying the human TTR Ile84Ser mutation was created and shown to express high levels of human mutant transthyretin. TTR ASOs suppressed hepatic TTR mRNA levels and serum TTR levels by as much as 80%. Suppression of hepatic synthesis of transthyretin may offer a medical treatment for transthyretin systemic amyloidosis.

AB - Transthyretin (TTR) amyloidosis, the most common form of hereditary systemic amyloidosis, is characterized clinically by adult-onset axonal neuropathy and restrictive cardiomyopathy. More than 85 mutations in transthyretin have been found to cause this hereditary disease. Since essentially all circulating TTR is of hepatic origin, orthotopic liver transplantation has been used as the only specific form of therapy. Unfortunately, in many patients amyloid deposition continues after orthotopic liver transplantation, indicating that mutant TTR is no longer required for progression of the disease after tissue deposits have been initiated. As a first step toward medical treatment of this disease, we have employed antisense oligonucleotides (ASOs) to inhibit hepatic expression of TTR. A transgenic mouse model carrying the human TTR Ile84Ser mutation was created and shown to express high levels of human mutant transthyretin. TTR ASOs suppressed hepatic TTR mRNA levels and serum TTR levels by as much as 80%. Suppression of hepatic synthesis of transthyretin may offer a medical treatment for transthyretin systemic amyloidosis.

KW - Amyloidosis

KW - Antisense oligonucleotide (ASO)

KW - Cardiomyopathy

KW - DNA

KW - Familial amyloidotic polyneuropathy

KW - Hereditary systemic amyloidosis

KW - Transgenic mouse model

UR - http://www.scopus.com/inward/record.url?scp=33646244247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646244247&partnerID=8YFLogxK

U2 - 10.1002/mus.20503

DO - 10.1002/mus.20503

M3 - Article

VL - 33

SP - 609

EP - 618

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 5

ER -